Ionis Pharmaceuticals Inc (NAS:IONS)
$ 35.91 -0.42 (-1.16%) Market Cap: 5.74 Bil Enterprise Value: 4.73 Bil PE Ratio: 0 PB Ratio: 8.65 GF Score: 40/100

Ionis Pharmaceuticals Inc To Discuss Eplontersen NEURO-TTRansform 66-Week Results Call Transcript

Apr 25, 2023 / 05:00PM GMT
Release Date Price: $35.88 (+0.45%)
Operator

Good afternoon, and welcome to Ionis' conference call to review the Phase III data for eplontersen. As a reminder, this call is being recorded. At this time, I would like to turn the call over to Wade Walke, Senior Vice President of Investor Relations, to lead off the call. Please begin.

D. Wade Walke
Ionis Pharmaceuticals, Inc. - SVP of IR

Thank you, Jason. Hello, and thank you for joining us as we discuss the results from our Phase III NEURO-TTRansform study of eplontersen in patients with hereditary ATTR polyneuropathy, which were presented yesterday at the American Academy of Neurology Annual Meeting. Before we begin, I encourage everyone to go to the Investors section of the Ionis website to view the press release we issued yesterday as well as the AAN presentation and poster and the slides we will be using on today's webcast.

I would first like to draw your attention to Slide 2, which contains our forward-looking statements. Our discussion today will contain forward-looking statements based on our current expectations and beliefs. Such

Already have an account? Log in
Get the full story
Access to All Earning Calls and Stock Analysis
30-Year Financial on one screen
All-in-one Stock Screener with unlimited filters
Customizable Stock Dashboard
Real Time Insider Trading Transactions
8,000+ Institutional investors’ 13F holdings
Powerful Excel Add-in and Google sheets Add-on
All data downloadable
Quick customer support
And much more...
30-Day 100% money back guarantee
You are not charged until the trial ends. Subscription fee may be tax deductible.
Excellent
4.6 out of 5 Trustpilot